BioSpace News Archive

CRH Medical Corporation, announces that it has received approval from the Toronto Stock Exchange of its Notice of Intention to renew its existing Normal Course Issuer Bid.

Baxter International Inc., a leading global medical products company, will present at the Evercore ISI 2nd Annual HealthCONx Conference in Boston on December 4, 2019.

Cellular Biomedicine Group Inc., a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported its financial results and business highlights for the third quarter of 2019.

Inari Medical, Inc. announced the presentation of early outcomes from the ClotTriever Outcomes Registry using the ClotTriever Mechanical Thrombectomy System for treatment of acute and chronic lower extremity deep vein thrombosis Initial results for the first 50 patients were presented by principal investigator David J. Dexter, MD, a vascular surgeon at Sentara Healthcare in Norfolk, VA at the VIVA 2019 late-breaking clinical trials session held in Las Vegas, NV.

First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma

ADMA Biologics, Inc. announced financial results for the third quarter and nine months ended September 30, 2019, and provided an overview of its recent corporate achievements.

Biostage, Inc., a bioengineering company developing next-generation esophageal implants, announced that it will report its financial results for the three and nine months ended September 30, 2019 in a press release that will be issued pre-market on Tuesday November 12, 2019.

The first innovative treatment for the treatment of vulvovaginal atrophy with prasterone

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 61st Annual American Society of Hematology (ASH) meeting being held December 7-10, 2019 in Orlando, Florida.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 14, 2019 to report its third quarter 2019 financial results and provide a corporate update.